Market Overview:
The global anti-tuberculosis medicine market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of tuberculosis (TB), increasing awareness about TB, and growing demand for novel drugs and therapies. However, the high cost of treatment is a major restraint on the growth of this market. The global anti-tuberculosis medicine market can be segmented by type, application, and region. By type, the market can be divided into isoniazid, rifampin, ethambutol, pyrazinamide, and other drugs. By application, the market can be classified into hospitals and clinics; government agencies; non-profit organizations; research institutes; pharmaceutical companies; contract research organizations (CROs); others (including retail pharmacies). The regional segmentation includes North America,, Latin America,, Europe,, Asia Pacific,, Middle East & Africa,.
Product Definition:
Anti-tuberculosis Medicine is a type of medication that is used to help treat tuberculosis (TB). TB is a serious infection that can affect the lungs and other parts of the body. Anti-tuberculosis medications can help kill the bacteria that cause TB, which can help improve symptoms and reduce the risk of spreading the infection.
Isoniazid:
Isoniazid is an anti-tuberculosis drug and is used in the treatment of Tuberculosis (TB). It works by killing the bacteria that causes TB. Isoniazid was first approved by the U.S. FDA in 1961, and it has been a part of standard anti-tuberculosis medication ever since.
Rifampin:
Rifampin is an antibiotic drug and is used in the treatment of tuberculosis. It works by killing the bacteria that causes tuberculosis. Rifampin can be used with other antibiotics to treat active TB, but it has been found to be more effective when used alone. The drug was first approved by the U.
Application Insights:
The others segment held the largest share of the global anti-tuberculosis medicine market in 2017. This is due to a high prevalence of tuberculosis among other applications such as HIV and drug-resistant TB. According to WHO, around 10 million people were diagnosed with multi-drug resistant TB in 2015 globally, which was about 6% of all cases reported worldwide. In addition, around 2 million people died from this disease that same year owing to multi-drug resistant TB; thus accounting for about 1 in 5 deaths caused by tuberculosis worldwide.
Government agencies accounted for a significant share within the application segment due to increasing government spending on healthcare and rising need for advanced drugs that can cure multidrugresistant tuberculosis (MDRTB).
Regional Analysis:
Asia Pacific dominated the global market in 2017. The region is expected to witness a CAGR of XX% over the forecast period, owing to high prevalence of tuberculosis and increasing government initiatives for drug treatment. According to WHO, India has one of the highest number of latent cases in the world with 1 million people living with active tuberculosis (TB) infection but are not aware that they have it. This accounts for nearly 60% TB cases diagnosed annually in India while approximately 50% remain undiagnosed and untreated leading to high incidence rates over time which further increases burden on healthcare system and economy at large eventually affecting growth rate negatively.
North America also held a significant share followed by Europe due as otherr anti-tuberculosis drugs are not only expensive but also have severe side effects compared to isoniazid or rifampin based drugs thus hinder its usage rate significantly thereby hampering regional growth prospects majorly in Central & South America (CSA).
Growth Factors:
- Increasing incidence of tuberculosis (TB) across the globe
- Growing awareness about the disease and its treatment options
- Rising demand for anti-TB drugs in developing countries
- Technological advancements in drug discovery and development process
- increasing funding for research and development of new TB drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-tuberculosis Medicine Market Research Report
By Type
Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Otherr
By Application
Hospitals and Clinics, Government Agencies, Non-Profit Organizations, Others
By Companies
Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, Chongqing Huapont Pharm, Shuangding Pharm, Hongqi pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
160
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Anti-tuberculosis Medicine Market Report Segments:
The global Anti-tuberculosis Medicine market is segmented on the basis of:
Types
Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Otherr
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Government Agencies, Non-Profit Organizations, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lupin
- Macleods Pharmaceuticals
- Otsuka Pharmaceutical
- Johnson & Johnson
- Pfizer
- Novartis
- Abbott
- AstraZeneca
- Bayer
- Eli Lilly
- GlaxoSmithKline
- Merck
- Sanofi
- Chongqing Huapont Pharm
- Shuangding Pharm
- Hongqi pharmaceutical
Highlights of The Anti-tuberculosis Medicine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Isoniazid
- Rifampin
- Ethambutol
- Pyrazinamide
- Otherr
- By Application:
- Hospitals and Clinics
- Government Agencies
- Non-Profit Organizations
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-tuberculosis Medicine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-tuberculosis medicine is a medication used to treat tuberculosis. It is usually taken by mouth, but can also be given by injection into the bloodstream. Anti-tuberculosis medicines work to kill the bacteria that cause tuberculosis, and may also help reduce the number of symptoms a person experiences.
Some of the major companies in the anti-tuberculosis medicine market are Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, Chongqing Huapont Pharm, Shuangding Pharm, Hongqi pharmaceutical.
The anti-tuberculosis medicine market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-tuberculosis Medicine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-tuberculosis Medicine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-tuberculosis Medicine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-tuberculosis Medicine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-tuberculosis Medicine Market Size & Forecast, 2018-2028
4.5.1 Anti-tuberculosis Medicine Market Size and Y-o-Y Growth
4.5.2 Anti-tuberculosis Medicine Market Absolute $ Opportunity
Chapter 5 Global Anti-tuberculosis Medicine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Anti-tuberculosis Medicine Market Size Forecast by Type
5.2.1 Isoniazid
5.2.2 Rifampin
5.2.3 Ethambutol
5.2.4 Pyrazinamide
5.2.5 Otherr
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Anti-tuberculosis Medicine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Anti-tuberculosis Medicine Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Government Agencies
6.2.3 Non-Profit Organizations
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-tuberculosis Medicine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-tuberculosis Medicine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anti-tuberculosis Medicine Analysis and Forecast
9.1 Introduction
9.2 North America Anti-tuberculosis Medicine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anti-tuberculosis Medicine Market Size Forecast by Type
9.6.1 Isoniazid
9.6.2 Rifampin
9.6.3 Ethambutol
9.6.4 Pyrazinamide
9.6.5 Otherr
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Anti-tuberculosis Medicine Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Government Agencies
9.10.3 Non-Profit Organizations
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Anti-tuberculosis Medicine Analysis and Forecast
10.1 Introduction
10.2 Europe Anti-tuberculosis Medicine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anti-tuberculosis Medicine Market Size Forecast by Type
10.6.1 Isoniazid
10.6.2 Rifampin
10.6.3 Ethambutol
10.6.4 Pyrazinamide
10.6.5 Otherr
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Anti-tuberculosis Medicine Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Government Agencies
10.10.3 Non-Profit Organizations
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Anti-tuberculosis Medicine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anti-tuberculosis Medicine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anti-tuberculosis Medicine Market Size Forecast by Type
11.6.1 Isoniazid
11.6.2 Rifampin
11.6.3 Ethambutol
11.6.4 Pyrazinamide
11.6.5 Otherr
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Anti-tuberculosis Medicine Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Government Agencies
11.10.3 Non-Profit Organizations
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Anti-tuberculosis Medicine Analysis and Forecast
12.1 Introduction
12.2 Latin America Anti-tuberculosis Medicine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anti-tuberculosis Medicine Market Size Forecast by Type
12.6.1 Isoniazid
12.6.2 Rifampin
12.6.3 Ethambutol
12.6.4 Pyrazinamide
12.6.5 Otherr
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Anti-tuberculosis Medicine Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Government Agencies
12.10.3 Non-Profit Organizations
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Anti-tuberculosis Medicine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anti-tuberculosis Medicine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anti-tuberculosis Medicine Market Size Forecast by Type
13.6.1 Isoniazid
13.6.2 Rifampin
13.6.3 Ethambutol
13.6.4 Pyrazinamide
13.6.5 Otherr
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Anti-tuberculosis Medicine Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Government Agencies
13.10.3 Non-Profit Organizations
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-tuberculosis Medicine Market: Competitive Dashboard
14.2 Global Anti-tuberculosis Medicine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Lupin
14.3.2 Macleods Pharmaceuticals
14.3.3 Otsuka Pharmaceutical
14.3.4 Johnson & Johnson
14.3.5 Pfizer
14.3.6 Novartis
14.3.7 Abbott
14.3.8 AstraZeneca
14.3.9 Bayer
14.3.10 Eli Lilly
14.3.11 GlaxoSmithKline
14.3.12 Merck
14.3.13 Sanofi
14.3.14 Chongqing Huapont Pharm
14.3.15 Shuangding Pharm
14.3.16 Hongqi pharmaceutical
